Melanoma: all 3,073 studies
Page 21 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.
- Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal MelanomaCompletedNCT02843386Phase 3
- Study of Anti-telomerase T CD4 Immunity in MelanomaStatus unknownNCT02838433Not applicable
- HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced MelanomaCompletedNCT02836548Phase 1/2
- A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)CompletedNCT02831634Not applicable
- Bio-marker Analysis Using Circulating Tumor Cells in Patients With MelanomaWithdrawnNCT02828345
- X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedNCT02823405Phase 1
- A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.CompletedNCT02821182Phase 2
- Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
- Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
- Nivolumab Plus Radiotherapy in Advanced MelanomaCompletedNCT02799901Phase 2
- Interferon Toxicities in Melanoma TreatmentCompletedNCT02794636
- GI Complications in Cancer Immunotherapy PatientsStatus unknownNCT02784366
- Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyCompletedNCT02780089
- Intermittent Selumetinib for Uveal MelanomaCompletedNCT02768766Phase 1
- A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedNCT02768207Phase 2
- Pembrolizumab-PET ImagingCompletedNCT02760225Not applicable
- In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant MelanomaStatus unknownNCT02759536Phase 1/2
- Ipilimumab-induced Lung Toxicity: Observational StudyCompletedNCT02755233
- Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma PatientsTerminatedNCT02744209
- Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune DiseasesCompletedNCT02739386
- A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced MelanomaCompletedNCT02738489Phase 1
- Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneWithdrawnNCT02736123Phase 1/2
- First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsCompletedNCT02729298Phase 1
- Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesCompletedNCT02724488
- XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingNCT02721459Phase 1
- Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaWithdrawnNCT02719015Phase 1/2
- Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.TerminatedNCT02718391Phase 2
- Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant MelanomaCompletedNCT02717364
- SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or SpineCompletedNCT02716948Phase 1
- Early FDG PET in MelanomaTerminatedNCT02716077Not applicable
- Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
- RATIO: Rational Approach To Immuno-OncologyCompletedNCT02700971Not applicable
- [18F]Dabrafenib Molecular Imaging in Melanoma Brain MetastasisTerminatedNCT02700763Not applicable
- Impact of Obstructive SAS on Metastatic Potential of Cutaneous MelanomaWithdrawnNCT02699918Early Phase 1
- Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the EyeCompletedNCT02697630Phase 2
- Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected MelanomaCompletedNCT02696356Phase 1
- Understanding Immunotherapy Resistance Mechanisms in Advanced MelanomaCompletedNCT02694965
- Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedNCT02680184Phase 1
- Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaCompletedNCT02676869Phase 1
- A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma PatientsStatus unknownNCT02671513Phase 1
- Employment and Quality of Life in Patients With Malignant MelanomaCompletedNCT02668887
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesTerminatedNCT02668770Phase 1
- A Sunscreen Based on Bioadhesive NanoparticlesCompletedNCT02668536Phase 1
- A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)WithdrawnNCT02663258Phase 2
- Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain MetastasesCompletedNCT02662725Phase 2
- A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
- Study With T-cel Receptor Gene Therapy in Metastatic MelanomaStatus unknownNCT02654821Phase 1/2
- Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedNCT02652455Early Phase 1
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
- Immunostimulating Interstitial Laser Thermotherapy in Malignant MelanomaTerminatedNCT02650492Not applicable
- Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic MelanomaCompletedNCT02645149Phase 2
- Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
- Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2
- Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesCompletedNCT02626065Phase 4
- Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma PatientsStatus unknownNCT02625337Phase 2
- Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesTerminatedNCT02621515Phase 2
- A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma PatientsStatus unknownNCT02619058Phase 1
- Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic MelanomaActive, not recruitingNCT02617849Phase 2
- fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma DepthCompletedNCT02613325Phase 1
- Melanoma Image Analysis Algorithm (MIAA) Validation StudyCompletedNCT02612168Not applicable
- A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma PatientsStatus unknownNCT02608437Phase 1
- A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateCompletedNCT02608034Phase 1
- Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal MelanomasTerminatedNCT02602756Not applicable
- A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.TerminatedNCT02601378Phase 1
- Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With PembrolizumabCompletedNCT02600169
- Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.CompletedNCT02600143
- MRI and PET to Assess Pembrolizumab ResponseTerminatedNCT02591654Early Phase 1
- Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT02583516Phase 2
- Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of ImmunotherapyStatus unknownNCT02581228
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsCompletedNCT02575404Phase 1
- Pilot Study of Vigil™ + Pembrolizumab for Advanced MelanomaCompletedNCT02574533Phase 1
- myDC/pDC in Stage III Melanoma PatientsCompletedNCT02574377Phase 1/2
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
- Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedNCT02565992Phase 1
- PV-10 in Combination With Pembrolizumab for Treatment of Metastatic MelanomaActive, not recruitingNCT02557321Phase 1/2
- Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain MetastasisCompletedNCT02537600Phase 2
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawnNCT02535078Phase 1/2
- Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2
- Digital vs. Printed Photographs: Impact on Skin Self-ExaminationsCompletedNCT02520622Not applicable
- A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCompletedNCT02516527Phase 1
- Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of MelanomaStatus unknownNCT02511119
- Videoscopic Ilioinguinal Lymphadenectomy for MelanomaCompletedNCT02508909Not applicable
- SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial AccessWithdrawnNCT02507947
- Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or SarcomaWithdrawnNCT02507076Not applicable
- Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line TherapyStatus unknownNCT02501551Phase 2
- PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced MelanomaCompletedNCT02492815
- In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
- Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory MelanomaCompletedNCT02482532Phase 1
- Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)CompletedNCT02470273
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisStatus unknownNCT02460068Phase 3
- ImmuniCell® in Patients With Advanced CancersTerminatedNCT02459067Phase 2
- Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)Status unknownNCT02452294Phase 2
- Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaWithdrawnNCT02452281Phase 1/2